Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy

Neurology

Volumn 52, Issue 3, 1999, Pages 607-613

  Childs, E A ^a   Lyles, R H ^a   Selnes, O A ^b   Chen, B ^a   Miller, E N ^c   Cohen, B A ^d   Becker, J T ^f   Mellors, J ^f   McArthur, Justin C ^a,b,e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RNA;

ADULT; AIDS RELATED COMPLEX; ARTICLE; DEMENTIA; DISEASE COURSE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSORY NEUROPATHY; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0033015441     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.3.607     Document Type: Article

References (34)

1. Bouwman FH, Skolasky R, Hes D, et al. Variable progression of HIV-associated dementia. Neurology 1998;50:1814-1820.
2. McArthur JC, Grant I. HIV neurocognitive disorders. In: Gendelman HE, Lipton SA, Epstein L, Swindells S, eds. The neurology of AIDS. New York: Chapman and Hall, 1998:499-523.
3. McArthur JC. Neurologic manifestations of AIDS. Medicine (Baltimore) 1987;66:407-437.
4. McArthur JC, Cohen BA, Seines OA, et al. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1-infected individuals: results from the Multicenter AIDS Cohort Study. Ann Neurol 1989;26:601-611.
5. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1 related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994;44:1892-1900.
6. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-1738.
7. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993;43: 2245-2252.
8. Ho DD, Mougdil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-1625.
9. Venet A, Lu W, Beldjord K, Andrieu JM. Correlation between CD4 cell counts and cellular and plasma viral load in HIV-1-seropositive individuals. AIDS 1991;5:283-288.
10. Paul DA, Falk LA, Kessler HA, et al. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol 1987;22:357-363.
11. Goudsmit J, de Wolf F, Paul DA, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1986;2:177-180.
12. Coombs RW, Collier AC, Allain JP, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989; 321:1626-1631.
13. Schooley RT. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS 1995; 9(suppl 2):S15-S19.
14. Hogervorst E, Jurriaans S, Dewolf F, et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995;171:811-821.
15. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
16. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
17. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4(+) lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997;126:939-945.
18. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to (CD4+) lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-938.
19. Spector SA, Hsia K, Pratt D, et al. Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid. J Infect Dis 1993;168:68-74.
20. Ho DD, Pomerantz RJ, Kaplan JC. Pathogenesis of infection with human immunodeficiency virus. N Engl J Med 1987;317: 278-286.
21. Sei S, Stewart SK, Farley M, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996;174:1200-1206.
22. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997; 175:963-966.
23. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997;42:689-698.
24. Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 1997;42:679-688.
25. Robertson K, Fiscus S, Kapoor C, et al. CSF, plasma viral load and HIV associated dementia. J Neurovirol 1998;4:90-94.
26. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study (MACS): rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-318.
27. Working Group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Neurology 1991;41:778-785.
28. Todd J, Pachl C, White R, et al. Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(suppl 2):S35-S44.
29. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of lymphocyte-T subsets: the Multicenter AIDS Cohort Study experience. Clin Immunol Immunopathol 1990;55:173-186.
30. Lipton SA, Gendelman HE. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995;332: 934-940.
31. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy (abstract 184). 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; February 1-5, 1998.
32. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown, 1987.
33. Berger AR, Arezzo JC, Schaumburg HH, et al. 2′,3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993;43:358-362.
34. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9: 153-161.